IL92495A - Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor - Google Patents

Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor

Info

Publication number
IL92495A
IL92495A IL9249589A IL9249589A IL92495A IL 92495 A IL92495 A IL 92495A IL 9249589 A IL9249589 A IL 9249589A IL 9249589 A IL9249589 A IL 9249589A IL 92495 A IL92495 A IL 92495A
Authority
IL
Israel
Prior art keywords
interferon
squamous cell
cell carcinoma
treatment
intralesionally
Prior art date
Application number
IL9249589A
Other languages
English (en)
Hebrew (he)
Other versions
IL92495A0 (en
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL92495A0 publication Critical patent/IL92495A0/xx
Publication of IL92495A publication Critical patent/IL92495A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL9249589A 1988-12-01 1989-11-29 Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor IL92495A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27831588A 1988-12-01 1988-12-01

Publications (2)

Publication Number Publication Date
IL92495A0 IL92495A0 (en) 1990-08-31
IL92495A true IL92495A (en) 1995-05-26

Family

ID=23064525

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9249589A IL92495A (en) 1988-12-01 1989-11-29 Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor

Country Status (14)

Country Link
EP (2) EP0446279A1 (de)
JP (1) JPH0647556B2 (de)
KR (1) KR950011889B1 (de)
AT (1) ATE92333T1 (de)
AU (1) AU634511B2 (de)
CA (1) CA2004202C (de)
DE (1) DE68908119T2 (de)
DK (1) DK103891A (de)
ES (1) ES2058555T3 (de)
IE (1) IE63121B1 (de)
IL (1) IL92495A (de)
MY (1) MY107071A (de)
WO (1) WO1990006135A1 (de)
ZA (1) ZA899113B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503570A (ja) * 1990-12-14 1994-04-21 シェリング・コーポレーション 肺の悪性腫瘍類を治療するためのアルファーインターフェロンの経口投与
IL100415A0 (en) * 1990-12-21 1992-09-06 Schering Corp Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
EP0859630B1 (de) * 1995-10-04 2002-12-11 Schering Corporation Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs
US7294332B2 (en) 1995-10-04 2007-11-13 Schering Corporation Combination therapy (temozolomide and α-IFN) for advanced cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077063B1 (de) * 1981-10-13 1988-03-16 Exovir, Inc. Interferon enthaltende Zusammensetzungen und die Anwendung dieser Zusammensetzungen in der Behandlung von Herpesinfektionen, prämalignen Hautverletzungen, Hautmalignitäten und Psoriasis
IE62318B1 (en) * 1986-05-27 1995-01-25 Schering Corp Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon

Also Published As

Publication number Publication date
AU634511B2 (en) 1993-02-25
IE63121B1 (en) 1995-03-22
MY107071A (en) 1995-09-30
KR950011889B1 (ko) 1995-10-12
KR900701311A (ko) 1990-12-01
EP0372809A1 (de) 1990-06-13
DE68908119D1 (de) 1993-09-09
AU4802590A (en) 1990-06-26
ES2058555T3 (es) 1994-11-01
EP0446279A1 (de) 1991-09-18
IL92495A0 (en) 1990-08-31
DK103891D0 (da) 1991-05-31
ZA899113B (en) 1990-08-29
DK103891A (da) 1991-05-31
ATE92333T1 (de) 1993-08-15
CA2004202A1 (en) 1990-06-01
EP0372809B1 (de) 1993-08-04
DE68908119T2 (de) 1993-11-18
WO1990006135A1 (en) 1990-06-14
JPH04500678A (ja) 1992-02-06
CA2004202C (en) 2001-02-13
JPH0647556B2 (ja) 1994-06-22
IE893828L (en) 1990-06-01

Similar Documents

Publication Publication Date Title
DE60031999T2 (de) Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
Wickramasinghe et al. Treatment of neoplastic skin lesions with intralesional interferon
US5028422A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5256410A (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
IE64765B1 (en) Use of cytokines
Edwards et al. Effect of intralesional a2-interferon on actinic keratoses
US5480640A (en) Alpha interferon for treating prostate cancer
US5002764A (en) Treatment of actinic keratoses with alpha2 interferon
EP0225759B1 (de) Interferon-Zusammensetzungen
AU634511B2 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
Doǧan et al. Intralesional alfa-2a interferon therapy for basal cell carcinoma
EP0248583B1 (de) Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons
Bleeker Intralesional triamcinolone acetonide using the Port‐O‐Jet and needle injections in localized dermatoses
Ikić et al. Interferon reduces recurrences of basal cell and squamous cell cancers
EP0369632A1 (de) Behandlung von Genitalwarzen mit einer Mischung von flüssigem Stickstoff und rekombinantem DNA-h-alpha-Interferon
Hussein Interleukin 1 protects against 1-β-D-arabinofuranosylcytosine-induced alopecia in the newborn rat animal model
Brody Electrical Activity in Sympathetic Nerves of Immunologically Sympathectomized Rats.
Shuttleworth et al. A comparison of the effects of intralesional interferon α-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease
Lee et al. Clinical trials of interferon-gamma in treating warts
CA1295244C (en) Treatment of actinic keratoses with alpha interferon
Jackson Treatment of superficial epitheliomatosis with an ointment containing demecolcin
Cho et al. Basal Cell Carcinoma and Actinic Keratosis Treated with Intralesional Injection of Recombinant Alpha-2 Interferon
von Wussow INTRALESIONAL INTERFERON-ALPHA-THERAPY IN ADVANCED MALIGNANT MELANOMA Peter von Wussow Dept. of Clinical Immunology, Medical School of Hannover, Hannover, West-Germany
Cho et al. Intralesional Injection of Recombinant Alpha-2 Interferon
EP0278715A2 (de) Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen

Legal Events

Date Code Title Description
RH Patent void